pt en es

Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Levamisole [14769-73-4]

Imprimir

Referencia HY-A0106-500mg

embalaje : 500mg

Contact local distributor :

Teléfono : +1 850 650 7790

Marca : MedChemExpress

Solicitar más información

Contact local distributor :

Teléfono : +1 850 650 7790

Descripciòn

Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC₅₀=300 μM) and α3β4 (EC₅₀=100 μM) subtype of nAChRs. Orally active^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: Levamisole	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27376493]
CCRF-CEM	IC₅₀	> 250 μM Compound: Levamisole	Cytotoxicity against human CEM cells after 72 hrs by Coulter counting method Cytotoxicity against human CEM cells after 72 hrs by Coulter counting method	[PMID: 25064346]
HeLa	IC₅₀	250 μM Compound: Levamisole	Cytotoxicity against human HeLa cells after 72 hrs by Coulter counting method Cytotoxicity against human HeLa cells after 72 hrs by Coulter counting method	[PMID: 25064346]
HeLa	IC₅₀	96 μM Compound: Levamisole	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27376493]
L1210	IC₅₀	206 μM Compound: Levamisole	Cytotoxicity against mouse L1210 cells after 48 hrs by Coulter counting method Cytotoxicity against mouse L1210 cells after 48 hrs by Coulter counting method	[PMID: 25064346]
MCF7	IC₅₀	> 100 μM Compound: Levamisole	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27376493]

In Vivo

(S)-(-)-Levamisole (Levamisole) (50 μg/ml and 200 μg/ml; p.o.; 30 days) prevents weight gain in mice that were fed a high fat diet^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

204.30

Fòrmula

C₁₁H₁₂N₂S

No. CAS

14769-73-4

Appearance

Solid

Color

White to off-white

SMILES

C12=N[C@@H](C3=CC=CC=C3)CN1CCS2

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (489.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.8948 mL	24.4741 mL	48.9481 mL
5 mM	0.9790 mL	4.8948 mL	9.7896 mL
10 mM	0.4895 mL	2.4474 mL	4.8948 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureza y Documentación

Purity: 99.96%

Ficha de datos (274 KB) SDS (393 KB)

COA (248 KB) HNMR (88 KB) LCMS (223 KB) OR (94 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Lewis JA, et al. Levamisole: A Positive Allosteric Modulator for the α3β4 Nicotinic Acetylcholine Receptors Prevents Weight Gain in the CD-1 Mice on a High Fat Diet. Curr Pharm Des. 2017;23(12):1869-1872. [Content Brief]

[2]. Mehta KP, et al. Immunoregulatory treatment for minimal change nephrotic syndrome. Arch Dis Child. 1986;61(2):153-158. [Content Brief]